GLP-1 Mechanisms (7 Identified)
1. Direct L-Cell GLP-1 Secretion
Bitter taste receptor (TAS2R) → GPCR → cAMP↑ → PKAc + AMPK phosphorylation → GLP-1 release from NCI-H716 L cells. Timosaponin A3 (TA3) confirmed at 10 mg/kg in HFD mice.
In Vivo
In Vitro
2. DPP-4 Inhibition (Primary)
Mangiferin inhibits DPP-IV by 89% ± 8% in vitro — statistically equivalent to vildagliptin (90%) and sitagliptin (84%). Reduces serum DPP-IV from 44.53 → 15.26 λU/mL in HFD/STZ rats at 40 mg/kg.
In Vivo
3. SGLT-2 Inhibition (In Silico)
Neomangiferin outperforms dapagliflozin in molecular docking (−9.0 vs −8.3 kcal/mol). SGLT-1 inhibition in proximal intestine is linked to increased plasma GLP-1.
In Silico
4. Gut Microbiota → SCFA → GLP-1
Anemarrhena polysaccharide (AABP-1B) boosts Bacteroides/Prevotella, generating acetate (×3.69), propionate (×1.35), butyrate (×1.67) → GPR41/GPR43 → GLP-1 from colonic L cells.
In Vivo
5. AMPK Activation & Insulin Sensitization
Mangiferin, TA3, and sarsasapogenin activate AMPK, suppress NF-κB/JNK/IKK inflammation, restore IR/IRS-1/Akt signaling.
In Vivo
6. Direct Insulin Secretagogue (TH2)
Pertussis toxin-sensitive Gi/Ge protein pathway; TH2 fraction stimulates insulin secretion 2.5–11.9× in isolated islets.
In Vitro
7. Bile Acid Modulation → FXR/TGR5 → GLP-1
Anemarrhena rhizoma normalizes elevated bile acids in T2DM rats; bile acids regulate intestinal GLP-1 production via TGR5 receptor.
In Vivo
Key Active Compounds
Mangiferin
Neomangiferin
Timosaponin A3
Timosaponin BII → AIII
Sarsasapogenin
AABP-1B Polysaccharide
TH2 fraction
Notable Synergy: Zhi Mu + Huang Bai
Timosaponin B2 elevates berberine bioavailability by 107–695%. The Zhimu-Huangbo combination achieves glucose lowering equivalent to metformin in GK rats, where neither compound alone is effective.
TCM Classification
Category: Clear Heat, Nourish Yin (清热滋阴)
Taste/Nature: Bitter, Sweet / Cold
Channels: Lung, Stomach, Kidney
Classic Formulas: Zhi Bai Di Huang Wan, Er Miao San
Xiaoke Connection: Upper/Lower Wasting (消渴) classic herb
TCM Classical
6–12
grams / day (dried rhizome)
Water decoction (煎剂). Used in formulas like Zhi Bai Di Huang Wan. Up to 30 g/day in intensive protocols.
Mangiferin (DPP-4)
40
mg/kg/day (animal → ~290 mg/day HED)
HFD/STZ rat study (Suman et al. 2016). FDA Km ratio = 6.2 for human equivalent dose.
Timosaponin A3 (TA3)
10
mg/kg × 3×/week (animal model)
Male C57BL/6J HFD mice (Park et al. 2024). Human equivalent ≈ 0.81 mg/kg/day.
Water Extract
90
mg/kg (KK-Ay mice model)
Miura et al. 2001. Reduced blood glucose 29.8% at 7h. HED (70 kg) ≈ 1,015 mg/day.
Synergy Combination
100
mg/kg total (TB-2 + Berberine combo)
Tian et al. 2019. TB-2 33.3 + BBR 66.7 mg/kg in GK rats. FBG ↓44.4%.
Safety Note
Safe
at therapeutic doses
Mild GI effects at high doses. Avoid in diarrhea, Yang deficiency cold patterns.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Antidiabetic activity of Anemarrhena rhizoma and mangiferin
|
Preclinical | KK-Ay mice | 90 mg/kg |
|
PubMed ↗ |
|
Insulin secretion stimulation by ethanol extract
|
Ex Vivo | GK rat isolated islets | TH2 fraction |
|
PubMed ↗ |
|
Mangiferin as DPP-IV inhibitor comparable to vildagliptin
|
Preclinical | HFD/STZ rats | 40 mg/kg/day × 6 wks |
|
PMC ↗ |
|
Timosaponin A3 activates GLP-1 secretion
|
Preclinical | HFD C57BL/6J mice | 10 mg/kg × 3×/wk |
|
PMC ↗ |
|
Anemarrhena polysaccharide reshapes gut microbiota → GLP-1
|
Preclinical | T2DM mouse models | AABP-1B oral |
|
PMC ↗ |
Contraindications & Cautions
- Contraindicated in Spleen deficiency diarrhea (苦寒伤阳)
- Avoid in Cold-type Yang deficiency patterns
- High-dose mangiferin isolate: no long-term human safety data
- Potential GI upset at high doses
- Use caution in pregnancy
- May potentiate hypoglycemic drugs
Safety Profile
- Long safety history in TCM at 6–12 g/day decoction doses
- No significant hepatotoxicity at therapeutic doses
- Mangiferin well-tolerated in all preclinical studies
- No completed human RCT on isolated Zhi Mu compounds
- Research gap: human PK/PD data for mangiferin needed
GLP-1 Mechanisms (4 Primary + 2 Additional)
1. Sweet Taste Receptor Pathway (Rg3)
Ginsenoside Rg3 activates T1R2/T1R3 sweet taste receptors → Gαgust → PLCβ2/IP3 + cAMP/PKA/CREB → GLP-1 secretion. Strongest of 15 ginsenosides (~27 pM/mg). 2-fold GLP-1 elevation in db/db mice.
In Vivo
In Vitro
2. TGR5/Bile Acid → L-Cell Expansion (Compound K)
Compound K activates TGR5 via secondary bile acids (LCA/DCA) → uniquely expands total L-cell population. Durable, long-term GLP-1 enhancement.
In Vivo
3. KATP Channel Pathway (Rb1/GTS)
Rb1/total ginsenoside saponins elevate ATP:ADP ratio → KATP channel closure → Ca²⁺ influx → GLP-1 release from L cells.
In Vitro
4. DPP-4 Inhibition (Red Ginseng Alkaloids)
Ginsenoside Rk, panaxadiol, Ro showed >50% DPP-4 inhibition. Clinically confirmed: DPP-4 ↓ (p=0.001) in 12-week RCT.
Clinical RCT
5. Gut Microbiome → L-Cell Expansion
Rb1 and Compound K reshape gut microbiota toward Akkermansia/Bacteroides → enhanced secondary bile acid → TGR5 + FFAR4 → durable L-cell expansion.
In Vivo
6. AMPK Activation (Multi-Ginsenoside)
Rb1/Rg1/Rg3/Re activate AMPK in skeletal muscle and liver → GLUT4 translocation, suppressed hepatic gluconeogenesis.
In Vivo
Key Active Compounds
Rg3 (direct secretagogue)
Compound K (L-cell expander)
Rb1 (KATP + microbiome)
Re (PPAR-γ + GLP-1)
Rg1 (α-glucosidase)
Rk (DPP-4 inhibitor)
Panaxadiol (DPP-4)
TCM Classification
Category: Tonify Qi (补气)
Taste/Nature: Sweet, Slightly Bitter / Neutral-Warm
Channels: Heart, Lung, Spleen
Forms studied: Red Ginseng (Hong Shen) has highest Rg3/CK
TCM Classical
3–9
grams / day (dried root decoction)
Up to 30 g/day in emergency Qi collapse. Standard for Xiaoke: 3–6 g/day in combination formulas.
Modern Extract (Best GLP-1)
500
mg/day standardized extract
Jeong et al. 2024 RCT (n=98): 500 mg/day RGEP × 12 weeks → +3.76 pM GLP-1, −DPP-4 (p=0.001).
Optimal Clinical Range
1,000–3,000
mg/day standardized extract
Or 3–6 g dry root equivalent. Korean Red Ginseng preferred for highest Rg3/CK content.
Insulin Sensitivity
5,000
mg/day KRG → 33% ISI improvement
Highest clinical evidence for insulin sensitivity improvement.
Standardization Target
4–7%
total ginsenosides
Look for Rg3 enrichment for optimal GLP-1 secretagogue effect.
Duration Needed
8–12
weeks minimum for GLP-1 effects
Microbiome-mediated L-cell expansion may require even longer.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Red Ginseng Extract Powder (RGEP) RCT on GLP-1 & DPP-4
|
Clinical RCT | n=98 T2DM patients | 500 mg/day × 12 wks |
|
2024 |
|
Ginsenoside Rg3 activates T1R2/T1R3 → GLP-1
|
In Vitro | Human L cells / db/db mice | Rg3 various |
|
Preclinical |
|
Korean Red Ginseng 5 g/day for insulin sensitivity
|
Clinical | T2DM adults | 5,000 mg/day |
|
PubMed ↗ |
|
Meta-analysis: Ginseng effects on glycemic control
|
16 RCTs | 200–3,000 mg/day |
|
PubMed ↗ |
Contraindications & Cautions
- Ginseng Abuse Syndrome at very high doses (>15 g/day)
- Warfarin interaction: may potentiate anticoagulant effect
- Hypertension: Red Ginseng may raise BP at high doses
- Insomnia: avoid evening dosing
Safety Profile
- Excellent long-term safety record at 1–3 g/day
- Well-tolerated in 12-week RCTs at 500–3,000 mg extract
- One of the most studied herbal medicines globally
- Standardization critical: ginsenoside content varies widely
GLP-1 Mechanisms (9 Distinct Pathways)
1. Direct GLP-1 Receptor Agonism (Geniposide)
Geniposide acts as a direct GLP-1R agonist → cAMP/PKA/Ca²⁺ → glucose-stimulated insulin secretion. Only TCM compound with direct GLP-1R agonist activity.
In Vivo
In Vitro
2. UCP2 Inhibition in Beta Cells (Genipin)
Genipin potently inhibits UCP2 → ↑ ΔΨm → ↑ ATP → KATP closure → Ca²⁺ influx → insulin secretion. Published in Cell Metabolism (2006).
Cell Metabolism 2006
3. UCP2 Inhibition in L-Cells → GLP-1↑
Genipin inhibits UCP2 in intestinal L cells → same ATP mechanism → ↑ endogenous GLP-1 secretion. Unique dual UCP2 target.
In Vivo
4. PLC/Ca²⁺ Pathway → ~5-fold GLP-1 Release
Genipin activates PLC → IP3 → intracellular Ca²⁺ → ~5-fold GLP-1 secretion from L cells. Independent of UCP2.
In Vitro
5. Alpha-Glucosidase Inhibition (Crocin I)
Crocin I inhibits α-glucosidase (IC50 = 0.204 mg/mL), reducing post-prandial glucose absorption rate.
In Vitro
6. AMPK Activation (Geniposide + Crocin)
Both compounds activate AMPK → hepatic/peripheral metabolic benefits → GLUT4↑, hepatic glucose output↓.
In Vivo
7. Beta-Cell Protection via GLP-1R/AMPK/TCF7L2
Geniposide activates GLP-1R → AMPK → TCF7L2 → beta cell regeneration and protection from apoptosis.
In Vivo
Key Active Compounds
Geniposide (GLP-1R agonist)
Genipin (UCP2 inhibitor)
Crocin I & II (α-glucosidase)
Crocetin (antioxidant)
Genipin's Unique Dual UCP2 Target
Genipin is the only known natural compound that inhibits UCP2 in both pancreatic beta cells AND intestinal L cells simultaneously.
TCM Classification
Category: Clear Heat, Cool Blood (清热凉血)
Taste/Nature: Bitter / Cold
Channels: Heart, Lung, Triple Burner, Stomach
Classic Formulas: Zhi Zi Da Huang Tang, Yin Chen Hao Tang
TCM Classical
6–10
grams / day (Zhi Zi fruit decoction)
Contains 108–400 mg geniposide at standard doses.
Geniposide (Animal)
25–100
mg/kg/day (most studied range)
Min effective: 25 mg/kg. Most studies: 50 mg/kg. HED (50 mg/kg): ~567 mg/day.
Geniposide (Human Equiv.)
96–243
mg geniposide/day (from rat conversion)
TCM standard 6–10 g delivers 108–400 mg — overlapping research range.
Crocin Clinical Dose
30
mg/day (RCT-confirmed efficacy)
Behrouz 2020 RCT (n=50): FBS ↓19 mg/dL, HbA1c ↓0.44%, HOMA-IR ↓.
In Vitro (Genipin)
10–100
μM genipin for GLP-1 secretion
Wu et al. 2023. ~5-fold GLP-1 release at 10–100 μM.
Safety Ceiling
≤72.9
mg/kg/day geniposide (90-day NOAEL in rats)
Hepatotoxicity above 574 mg/kg. Standard TCM doses are safe.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Genipin inhibits UCP2 in beta cells — landmark study
|
In Vitro | Beta cells / UCP2-KO mice | Various μM |
|
Cell Metab ↗ |
|
Geniposide as GLP-1R agonist
|
In Vitro | INS-1 / STZ rats | 10 μM |
|
PMC ↗ |
|
Crocin supplementation RCT in T2DM
|
Clinical RCT | n=50 T2DM patients | 30 mg/day × 12 wks |
|
2020 RCT |
|
Geniposide protects beta cells via GLP-1R/AMPK/TCF7L2
|
Preclinical | T2DM mouse models | 25–50 mg/kg × 8 wks |
|
PMC ↗ |
Contraindications & Cautions
- Hepatotoxicity risk at high doses: Geniposide >574 mg/kg
- Contraindicated in diarrhea and Spleen-Stomach Cold deficiency
- Cold nature: caution in Yang deficiency patients
Safety Profile
- Standard TCM dose (6–10 g/day) delivers geniposide within safe range
- Crocin 30 mg/day safe in 12-week clinical trial
- Long TCM safety history at traditional doses
- Genipin isolate not yet in clinical trials for GLP-1
GLP-1 Mechanisms (Evidence-Graded)
1. DPP-4 Inhibition by 6-Gingerol (Strongest Preclinical)
6-gingerol significantly reduces plasma DPP-4 (p<0.001), extending endogenous GLP-1 half-life. 200 mg/kg/day in db/db mice dramatically ↑ plasma GLP-1. Exendin(9-39) fully abolished this effect — confirms GLP-1 as mediator.
In Vivo
2. Synergy with DPP-4 Inhibitors
6-Gingerol + saxagliptin co-administration was synergistic (p<0.0001) in db/db mice.
In Vivo
3. AMPK Activation (6-Shogaol / 6-Paradol)
6-shogaol (dried ginger) and 6-paradol activate AMPK → glucose uptake in muscle, hepatic glucose output suppression.
In Vivo
4. Gastric Emptying Acceleration
Ginger accelerates gastric emptying (12.3 vs 16.1 min, p<0.05). However, plasma GLP-1 was UNCHANGED — gastric effects are NOT via GLP-1.
Clinical (GLP-1 null)
5. L-Cell Stimulation via PLC Pathway (Proposed)
Proposed in 2025 review: gingerols/shogaols may stimulate L cells via PLC pathway. Not yet directly demonstrated.
Proposed (2025)
Key Active Compounds
6-Gingerol (DPP-4/GLP-1)
6-Shogaol (AMPK)
6-Paradol (AMPK metabolite)
Zingerone (anti-inflammatory)
TCM Classification
Category: Release Exterior / Warm Interior (解表/温里)
Taste/Nature: Pungent / Warm
Channels: Lung, Spleen, Stomach
Classic Formulas: Si Ni Tang, Wen Jing Tang, Li Zhong Wan
TCM (Sheng Jiang)
3–10
grams / day (fresh ginger)
Rich in 6-gingerol. Targets exterior cold, nausea.
TCM (Gan Jiang)
3–12
grams / day (dried ginger)
Rich in 6-shogaol (higher AMPK activity). Si Ni Tang, Li Zhong Wan formulas.
Optimal Clinical (HbA1c)
2–3
grams / day dried powder
Zhu et al. 2018 meta-analysis (n=490): HbA1c WMD −1.00%, FBG −21.24 mg/dL.
Animal Model (6-Gingerol)
200
mg/kg/day in db/db mice
DPP-4 reduction + GLP-1↑ confirmed. HED: ~1,613 mg/day.
Standardized Extract
2.0
grams 5% gingerol extract
~100 mg 6-gingerol content. Bioavailability <2%.
Best Combination
2–3 g
ginger extract + standard metformin
Preclinical: 74.2% glucose reduction (combo) vs 54.9% (ginger alone).
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Meta-analysis: Ginger on glycemic parameters in T2DM
|
n=490, 10 RCTs | Various; 8–12 wks |
|
PubMed ↗ | |
|
6-Gingerol reduces DPP-4 and elevates GLP-1 in db/db mice
|
Preclinical | db/db mice | 200 mg/kg/day |
|
Preclinical |
|
Ginger accelerates gastric emptying — GLP-1 unchanged
|
Clinical | n=11 healthy | 1.2 g dried |
|
PubMed ↗ |
|
Ginger 1.6 g/day RCT: FBG, HbA1c
|
Clinical RCT | n=88 T2DM | 1.6 g/day × 12 wks |
|
PubMed ↗ |
Contraindications & Cautions
- Blood thinning: caution with anticoagulants
- Bile duct disorders: avoid large doses
- Excess use may cause heartburn, GI irritation
- Human GLP-1 elevation NOT confirmed clinically
Safety Profile
- GRAS (Generally Recognized as Safe) status — FDA
- Excellent safety at 2–3 g/day in multiple clinical trials
- Anti-nausea, anti-inflammatory benefits
- Standardized extract quality varies widely
GLP-1 Mechanisms (5 Identified)
1. Direct L-cell GLP-1 Secretion
Berberine stimulates GLP-1 via proglucagon mRNA upregulation + L-cell proliferation (Lu 2009, GLP-1 3× increase in STZ rats). BBR metabolites berberrubine/palmatine protect GLUTag cells.
In Vivo
In Vitro
2. DPP-4 Inhibition
Berberine provides gut-local competitive DPP-4 inhibition; functionally analogous to gliptins. Partial inhibition due to low systemic bioavailability but high luminal concentration.
In Vitro
3. GLP-1R/PKA Signaling
Berberine activates GLP-1→GLP-1R→PKA→PC1/3→Pdx1 cascade. KCNH6 channel blockade → glucose-dependent insulin secretion (Zhao 2021, Nature Comms, Phase 1 RCT n=15, ↑second-phase insulin ~40%).
In Vivo
Phase 1 Clinical
4. AMPK Activation (Complex I Inhibition)
Berberine inhibits mitochondrial Complex I → AMP:ATP↑ → AMPK activation (mirrors metformin). dhBBR improves insulin sensitivity 44% (Turner 2008, Diabetes).
In Vivo
5. Gut Microbiome → SCFA → GLP-1
↑ Akkermansia, Bifidobacterium, Blautia; Blautia demethylates BBR → thalifendine → acetate + butyrate via GPR41/43 → L-cell GLP-1 secretion.
In Vivo
Key Active Compounds
Berberine (46–62%)
Coptisine (14–16%)
Palmatine (13–16%)
Epiberberine (11–15%)
Jatrorrhizine (2–4%)
Notable Synergy: Huang Lian + Zhi Mu
Timosaponin B2 elevates berberine bioavailability 107–695%; combination equals metformin in GK rats where neither works alone.
TCM Classification
Category: Clear Heat/Dry Damp (清热燥湿)
Taste/Nature: Bitter / Cold
Channels: Heart, Stomach, Large Intestine
Best Clinical Result: Yin 2008: BBR vs Metformin: HbA1c −2.0% vs −1.4%
TCM Classical
2–10
g/day decoction
Standard classical dose for clearing heat and drying dampness.
Modern Berberine
1,500
mg/day (500 mg TID with meals)
Most common modern clinical dosing. Take with meals for GI tolerability.
Best Clinical Result
HbA1c −2.0%
Yin 2008 RCT (BBR vs Metformin)
n=116: BBR 500mg TID vs MET 500mg TID × 3mo. BBR outperformed metformin.
Meta-analysis Result
−0.63%
HbA1c WMD (Su 2022, 33 RCTs)
n=2,846: FBG −0.82 mmol/L, 2hPBG −1.16 mmol/L.
Phase 1 Dose
KCNH6
mechanism confirmed (Zhao 2021)
Nature Comms, n=15: ↑ second-phase insulin ~40%.
Synergy Dose
TB-2 + BBR
combined in GK rats
Neither effective alone; combo equals metformin 200 mg/kg.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Berberine GLP-1 secretion in STZ rats
|
Preclinical | STZ rats | 125 mg/kg |
|
PubMed ↗ |
|
Berberine vs Metformin RCT
|
Clinical RCT | n=116 T2DM | 500mg TID × 3mo |
|
PubMed ↗ |
|
KCNH6 channel mechanism — Phase 1 RCT
|
Phase 1 RCT | n=15 | Phase 1 |
|
Nat Comms ↗ |
|
dhBBR insulin sensitivity — Complex I/AMPK
|
Preclinical | HFD mice | dhBBR |
|
PubMed ↗ |
|
Meta-analysis: 33 RCTs berberine
|
n=2,846 | Various doses |
|
Meta 2022 |
Contraindications & Cautions
- QTc prolongation risk at high doses
- CYP450 interactions (CYP3A4, 2D6)
- Avoid in pregnancy
- GI side effects common
- Not for Spleen/Stomach cold patterns
Safety Profile
- Long TCM safety history at 2–10 g/day
- Berberine 1,500 mg/day well-tolerated in RCTs
- Strongest clinical HbA1c reduction among all 13 herbs
- Monitor for drug interactions with CYP substrates
GLP-1 Mechanisms (5 Identified)
1. Direct L-cell stimulation
Berberine via PLC-β2 pathway + β-catenin/TCF4/miR-106b in intestinal L-cells.
In Vitro
2. DPP-4 Inhibition
Berberine IC50 = 13.3 µM at GLU205 active site; palmatine also a DPP-4 inhibitor.
In Vitro
3. Gut Microbiota → SCFA → GLP-1
Berberine + phellodendrine increase Akkermansia, Bifidobacterium → SCFAs → L-cell GLP-1.
In Vivo
4. AMPK Activation
Mitochondrial Complex I inhibition → AMP:ATP↑ → AMPK → suppresses gluconeogenesis, increases GLUT4.
In Vivo
5. Unique: Phellodendrine insulin receptor binding
Phellodendrine (absent in Huang Lian) directly binds insulin receptor (INSR −8.7 kcal/mol), activates PI3K/AKT. Magnoflorine: α-glucosidase inhibitor + PTP1B inhibitor (IC50 28.14 μM).
In Silico + In Vitro
Key Active Compounds
Berberine (0.6–3%)
Phellodendrine (unique marker)
Palmatine
Magnoflorine
Obacunone
Limonin
Key Differentiator from Huang Lian
Phellodendrine and limonoids are ABSENT from Huang Lian — these differentiate Huang Bai pharmacologically. Zhi Bai Di Huang Wan ranked #1 in 41-RCT network meta-analysis.
TCM Classification
Category: Clear Heat/Dry Damp (清热燥湿)
Taste/Nature: Bitter / Cold
Channels: Kidney, Bladder, Large Intestine
Key Formula: Zhi Bai Di Huang Wan (#1 ranked for FBG)
TCM Classical
3–12
g/day (decoction) or 1–3 g powder
Chuan Huang Bai: ≥3% berberine (higher). Guan Huang Bai: ≥0.60% berberine.
Berberine Equivalent
500–1,500
mg/day (from berberine content)
Lower berberine than Huang Lian — supplement if needed.
Zhi Bai Di Huang Wan
#1 Ranked
in 41-RCT network meta-analysis
3,562 patients: best for FBG AND urinary albumin reduction.
Palmatine Dose
500
mg/kg mouse OGTT
Reduced hepatic glucose output ~45%.
Magnoflorine
20
µg/mL insulin secretion stimulation
Also PTP1B inhibitor IC50 28.14 µM.
Safety Note
Lower Risk
than Huang Lian at standard doses
Lower berberine content means relatively lower risk profile.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Zhi Bai Di Huang Wan network meta-analysis
|
3,562 patients | Formula doses |
|
Meta-analysis | |
|
Phellodendrine INSR binding
|
In Silico | Molecular docking | Computational |
|
In Silico |
|
Magnoflorine α-glucosidase inhibition
|
In Vitro | Enzyme assay | Various |
|
In Vitro |
Contraindications & Cautions
- Similar to Huang Lian (cold, bitter)
- Avoid in Spleen-Stomach deficiency cold
- Long-term use may damage digestive function
Safety Profile
- Lower berberine content = lower risk at standard doses
- Long TCM safety history in classical formulas
- Zhi Bai Di Huang Wan formula well-validated
- Phellodendrine safety data limited
GLP-1 Mechanisms (5 Identified)
1. Direct L-cell GLP-1 Secretion via Ca²⁺/CaM
DOP directly stimulates GLP-1 from STC-1 L-cells via Ca²⁺/CaM/CaMKII + MAPK signaling. At 200 mg/kg/d in prediabetic mice, DOP significantly ↑ plasma GLP-1 while METFORMIN DID NOT.
In Vivo
In Vitro
2. Gut Microbiota → SCFA → FFAR2/3 → GLP-1
DOP prebiotic → fermented by Bifidobacterium/Lactobacillus/Roseburia → SCFAs → FFAR2/GPR43 + FFAR3/GPR41 → GLP-1 + PYY. OGTT AUC ↓54.2%, GPR41 ↑3×.
In Vivo
3. Glycerophospholipid Axis
D. nobile reduces phosphorylcholine → blocks lysophosphatidic acid synthesis → restores serum GLP-1, insulin, and glucose tolerance.
In Vivo
4. Beta-Cell Protection via Downstream GLP-1
GLP-1 secreted via DOP pathways activates GLP-1R → anti-apoptotic effects (↑ BCL-2, ↓ caspase-3); restores islet morphology.
In Vivo
5. Bile Acid → TGR5 → GLP-1
DOP modulates hepatic bile acid metabolism → TGR5 activation → additional GLP-1 and β-cell insulin enhancement.
In Vivo
Key Active Compounds
DOP (glucomannan polysaccharide)
Dendrobine (alkaloid)
Denbinobin (NF-κB inhibitor)
Gigantol (PI3K-AKT)
Moscatilin (α-glucosidase IC50 ~32 μM)
DOP vs Metformin — Unique Advantage
DOP at 200 mg/kg raised GLP-1 where metformin FAILED at the same dose — unique advantage for prediabetic intervention. 63.7% T2DM risk reduction vs 47.1% metformin.
TCM Classification
Category: Nourish Yin/Generate Fluids (养阴生津)
Taste/Nature: Sweet, slightly salty / Slightly Cold
Channels: Stomach, Kidney
Key Note: No human GLP-1 RCT yet — open research opportunity
TCM Classical
6–12
g dried stem/day (fresh 15–30 g)
Standard Shi Hu decoction dose.
DOP Effective Dose
200
mg/kg in prediabetic mice
↑GLP-1 where metformin failed. HED ~1,100 mg/day pure polysaccharide.
T2DM Risk Reduction
63.7%
vs 47.1% metformin (Liu 2023)
DOP in prediabetic mouse model outperformed metformin.
OGTT AUC Reduction
↓54.2%
at 200 mg/kg LDOP-A (Fang 2022)
Insulin⁺ β-cell area ↑1.34×, GPR41 ↑3×.
Moscatilin
IC50 ~32 μM
α-glucosidase inhibition
10× more potent than acarbose.
Research Opportunity
No Human RCT
GLP-1 mechanism not yet tested in humans
Strong preclinical rationale awaiting clinical translation.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
DOP 200 mg/kg in prediabetic mice vs metformin
|
Preclinical | Prediabetic mice | 200 mg/kg DOP |
|
PMC10296996 |
|
DOP in STC-1 cells — Ca²⁺/CaMKII mechanism
|
In Vitro | STC-1 L-cells | Various |
|
Carbohydr Polym 2020 |
|
LDOP-A in T2DM mice — OGTT/GPR41
|
Preclinical | T2DM mice | 200 mg/kg LDOP-A |
|
PMC9039915 |
|
Glycerophospholipid axis — GLP-1 restoration
|
Preclinical | D. nobile model | D. nobile extract |
|
PMC12300346 |
Contraindications & Cautions
- Avoid in early-stage pathogen invasion (may retain pathogen)
- Choose D. officinale vs D. nobile based on availability
Safety Profile
- One of the gentlest Yin-tonifying herbs
- Very few contraindications
- Food-grade safety profile in TCM tradition
- No human GLP-1 RCT data yet — animal data only
GLP-1 Mechanisms (4 Identified)
1. Cinnamaldehyde → TRPA1 → L-Cell GLP-1 (Primary)
Trans-cinnamaldehyde activates TRPA1 on intestinal L-cells via covalent modification → Ca²⁺ influx → GLP-1 exocytosis. CIN 20 mg/kg: +29% GLP-1, +100% insulin, −32% glucose. In vitro: +280% GLP-1. Abolished in trpa1−/− mice.
In Vivo
In Vitro
2. Human GLP-1 Elevation Confirmed
Hlebowicz 2009 (Am J Clin Nutr, n=15, crossover RCT): 3g cinnamon → significant ↑ GLP-1 ΔAUC (p=0.0082) + ↓ insulin AUC (p=0.036) with SAME blood glucose → improved insulin efficiency. 1g dose was INEFFECTIVE.
Clinical RCT
3. DPP-4 Inhibition (Weak)
Cinnamon polyphenolic fractions: IC50 205 μg/mL. ~41,000× less potent than sitagliptin. Minor contributor.
In Vitro
4. Procyanidin/MHCP Insulin Receptor Sensitization
Type-A proanthocyanidins + MHCP directly phosphorylate insulin receptor → PI3K → Akt → GLUT4 (232% at 10 μg/kg).
In Vivo
In Vitro
Key Active Compounds
Trans-cinnamaldehyde (TRPA1)
Cinnamate/Cinnamic acid
Procyanidin B2 (type-A)
Type-A proanthocyanidins (MHCP)
Coumarin
TCM Distinction: Gui Zhi vs Rou Gui
Gui Zhi (twig, 3–10 g/day) disperses outward; Rou Gui (bark, 1–5 g/day) warms inward/Kidney Yang. Most clinical T2DM studies use bark preparations — data applies directionally to both.
TCM Classification
Category: Release Exterior / Warm Yang (解表温阳)
Taste/Nature: Pungent, Sweet / Warm
Channels: Heart, Lung, Bladder
Key Human Evidence: Hlebowicz 2009: 3g → GLP-1 ↑ (p=0.0082)
TCM Classical (Gui Zhi)
3–10
g/day (twig)
Disperses outward. Release exterior, warm channels.
TCM Classical (Rou Gui)
1–5
g/day (bark)
Warms inward / Kidney Yang. Most clinical T2DM studies use bark.
Human GLP-1 Effective
3
g cinnamon (Hlebowicz 2009)
n=15: GLP-1 ΔAUC ↑ (p=0.0082). NOTE: 1g dose was INEFFECTIVE.
Khan 2003 FBG
1–6
g/day × 40 days (n=60)
FBG ↓18–29% in T2DM patients.
Ranasinghe 2025
250–500
mg/day × 4 months (n=186)
FBG ↓ p<0.05, HbA1c ↓ p<0.05.
Coumarin Safety
Limit
very high doses
EU restricts coumarin content. Use Ceylon cinnamon for lower coumarin.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
3g cinnamon → GLP-1 ↑ in humans
|
Clinical RCT | n=15 crossover | 3g cinnamon |
|
PubMed ↗ |
|
Cinnamaldehyde TRPA1 mechanism
|
Preclinical | Rats | 20 mg/kg CIN |
|
PMC10458466 |
|
TRPA1 confirmed in L-cells
|
Preclinical | L-cells / trpa1−/− mice | TRPA1 mechanism |
|
PMC4375100 |
|
Cinnamon 1-6g/day in T2DM
|
Clinical RCT | n=60 T2DM | 1/3/6g × 40d |
|
PubMed ↗ |
Contraindications & Cautions
- Avoid in Yin-deficient heat (warm herb)
- Coumarin content — limit very high doses; EU restricts coumarin
- Pregnancy: avoid large doses
- Drug interactions: anticoagulants (mild effect)
Safety Profile
- Well-tolerated at 1–6 g/day in clinical trials
- Long TCM safety history
- Ceylon cinnamon has lower coumarin than Cassia
- Human GLP-1 data confirmed (n=15)
GLP-1 Mechanisms (6 Identified)
1. Direct L-cell GLP-1 Secretion
Curcumin EC50 = 4.5 μM in STC-1 cells. Unstable oxidative metabolites covalently bind target cysteines, activating CaMKII, PKC, ERK. GPR40/120 is membrane receptor (Takikawa 2013).
In Vivo
In Vitro
2. DPP-4 Inhibition
~50% inhibition at 100 μM in vitro; 45% reduction DPP-4 activity at 100 mg/kg in obese rats; molecular docking −66.765 kcal/mol at S1 subsite.
In Vivo
In Vitro
3. AMPK Activation
Via LKB1-AMPK axis: ↑ p-AMPK Thr172, ↑ CPT-1, ↓ G6Pase/PEPCK 30%, ↑ GLUT4, ↑ glycogen synthesis.
In Vivo
4. NF-κB Suppression → Insulin Sensitization
Electrophilic covalent binding to IKKβ → ↓ TNF-α/IL-6/IL-1β → improved IRS-1 signaling. Potency: Curcumin > DMC > BDMC.
In Vivo
5. Gut Microbiome → TGR5 → GLP-1
↑ Lactobacillus, Bifidobacterium, butyrate producers → SCFAs → TGR5 + GPR41/43 → GLP-1 + L-cell expansion (Tian 2023, 60 mg/kg × 8 wks).
In Vivo
6. PPAR-γ Agonism
Turmerones (sesquiterpenoids): PPAR-γ ligands + α-glucosidase inhibition + insulin sensitizing.
In Vitro
Key Active Compounds
Curcumin (~75%)
Demethoxycurcumin DMC (~15%)
Bisdemethoxycurcumin BDMC (~5%)
α/ar/β-Turmerones
Bioavailability Critical
Conventional oral curcumin <1% systemic. Piperine ↑ 20×, nanoparticles ↑ 9–69×, nanomicelles ↑ >400×. Formulation choice is essential for efficacy.
TCM Classification
Category: Invigorate Blood / Move Qi (活血行气)
Taste/Nature: Pungent, Bitter / Warm
Channels: Spleen, Stomach, Liver
Landmark: Chuengsamarn 2012: 0% vs 16.4% T2DM progression
TCM Classical
3–10
g/day dried rhizome decoction
Standard decoction preparation.
Modern Clinical
1,000–1,500
mg/day curcumin extract
With bioavailability enhancer (piperine, nanomicelle, etc.).
T2DM Prevention
1,500
mg/day × 9 months (n=240)
Chuengsamarn 2012: 0% vs 16.4% T2DM progression.
Nanomicelle Form
80
mg/day (Rahimi 2016, n=70)
HbA1c −0.91 vs +0.33% (p=0.013). 400× better bioavailability.
HbA1c Result
6.12 vs 6.47%
Yaikwawong 2024, n=229, 12 mo
1,500 mg/day. FBG 115 vs 131 mg/dL.
Bioavailability Note
<1%
systemic without enhancer
MUST use piperine, nanoparticle, or nanomicelle formulation.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
T2DM prevention: 0% vs 16.4% progression
|
Clinical RCT | n=240 prediabetic | 1,500 mg/day × 9 mo |
|
Diabetes Care 2012 |
|
Curcumin 12-month RCT
|
Clinical RCT | n=229 T2DM | 1,500 mg/day × 12 mo |
|
Nutr J 2024 |
|
Nano-micelle curcumin
|
Clinical RCT | n=70 T2DM | 80 mg nano × 3 mo |
|
2016 RCT |
Contraindications & Cautions
- High-dose (>8g/day): nausea, diarrhea
- Avoid with blood-thinners (anticoagulant effect)
- Gallstone risk with concentrated extract
- Piperine increases drug absorption broadly
Safety Profile
- Very safe at standard doses
- Multiple large RCTs (n=240, n=229) confirm safety
- Long TCM and culinary safety history
- Bioavailability formulation critical for efficacy
GLP-1 Mechanisms (6 Identified)
1. DPP-4 Inhibition (EGCG)
EGCG IC50 = 28.42 μM at DPP-4 active site (Glu205, Glu206). In vivo: reduces DPP-IV activity and raises active GLP-1 (7-36) by +32% in HFD rats.
In Vivo
In Vitro
2. Direct L-Cell GLP-1 Stimulation
EC (epicatechin): +68% GLP-1 from GLUTag cells via PKA/cAMP. GTE + CCA raised human postprandial GLP-1 AUC +47% (Yanagimoto 2022, n=11).
In Vivo
Clinical RCT
3. Gut Microbiome → TGR5 → GLP-1
EGCG increases Akkermansia muciniphila ~500%, reshapes bile acid pool → TGR5 activation → GLP-1 + PYY.
In Vivo
4. AMPK Activation
EGCG → ROS → CaMKK → AMPK → suppresses PEPCK/G6Pase; hepatic gluconeogenesis inhibition at ≤1 μM.
In Vivo
5. Alpha-Glucosidase/Amylase Inhibition
Slows carbohydrate digestion → extends nutrient-stimulated GLP-1 secretion from distal L-cells.
In Vitro
6. SGLT1 Inhibition
GTE IC50 = 0.077 mg/mL for Caco-2 glucose uptake → reduces postprandial glucose load.
In Vitro
Key Active Compounds
EGCG (~60–65% catechins)
ECG
EGC
EC (epicatechin)
L-Theanine
Chlorogenic acid
Human GLP-1 Confirmed
Yanagimoto 2022 (n=11 crossover): GTE 620mg + CCA → GLP-1 AUC +47%, GIP ↓24%.
TCM Classification
Category: Clear Heat / Generate Fluids (清热生津)
Taste/Nature: Sweet, Bitter / Cool
Channels: Heart, Lung, Stomach
Best Evidence: Liu 2014: 856mg EGCG → GLP-1 ↑ p=0.001
TCM Classical
3–10
g dried leaf/day
Decoction yields ~300–640 mg EGCG.
Modern Clinical EGCG
300–800
mg EGCG/day (standardized extract)
~3–5 cups brewed green tea equivalent.
Best GLP-1 Result
856
mg EGCG × 16 wk (Liu 2014)
RCT T2DM n=92: GLP-1 ↑ p=0.001, HOMA-IR ↓ p=0.004.
GLP-1 AUC +47%
620
mg GTE + CCA (Yanagimoto 2022)
n=11 crossover: GLP-1 AUC +47%, GIP ↓24%.
Meta-analysis
15 RCTs
n=722 T2DM (Jia 2024)
FBG SMD −0.41, HbA1c SMD −0.68 (p=0.004).
HEPATOTOXICITY WARNING
>800mg
EGCG/day (fasting, supplement)
FDA issued warning. Take with food. 3–5 cups brewed tea = safe.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
GTE + CCA → GLP-1 AUC +47%
|
Clinical | n=11 crossover | 620mg GTE + CCA |
|
PMC9737369 |
|
856 mg EGCG RCT in T2DM
|
Clinical RCT | n=92 T2DM | 856 mg EGCG × 16 wk |
|
2014 RCT |
|
Meta-analysis: Green tea in T2DM
|
15 RCTs, n=722 | Various |
|
Meta 2024 | |
|
Akkermansia ↑500%, TGR5/GLP-1 pathway
|
Preclinical | Mouse model | EGCG |
|
PMC6219838 |
Contraindications & Cautions
- HEPATOTOXICITY risk above 800 mg EGCG/day (fasting, supplement form) — take with food
- FDA issued warning for EGCG supplements
- Caffeine content — avoid near bedtime
- Avoid with anticoagulants in very high extract doses
Safety Profile
- At 3–5 cups brewed tea: very safe
- Long global safety history as beverage
- Human GLP-1 elevation confirmed (n=11, n=92)
- EGCG >800mg fasting = hepatotoxicity risk
GLP-1 Mechanisms (5 Identified)
1. Direct L-Cell GLP-1 Secretion
Bupleurum hexane fraction stimulates GLP-1 ~25-fold in NCI-H716 human L-cells via Gβγ-PLCβ-IP3-Ca²⁺ pathway. Blood glucose significantly reduced in db/db mice OGTT (Shin 2014).
In Vivo
In Vitro
2. Hepatoprotection → Liver Insulin Sensitivity (SSc/SIRT6)
SSc activates SIRT6 → PPARα/NRF2 → hepatoprotection → restores liver IRS-1/PI3K/Akt signaling.
In Vivo
3. Anti-Inflammatory → GLP-1R Upregulation (SSa/SSd)
SSa/SSd inhibit NF-κB/TNF-α (via ERK/IκBα) → upregulated GLP-1 receptor expression on beta cells.
In Vivo
4. AMPK Activation (SSa/SSd)
Anti-adipogenic via AMPK activation → reduced adipose inflammation → improved peripheral insulin sensitivity.
In Vivo
5. Beta-Cell Protection (Polysaccharides)
Bupleurum polysaccharides protect β-cells → improved GSIS response to GLP-1 signal.
In Vitro
Key Active Compounds
Saikosaponin A (SSa)
Saikosaponin B2 (SSb2)
Saikosaponin C (SSc, SIRT6)
Saikosaponin D (SSd)
Bupleurum polysaccharides
Rutin
Isorhamnetin
Xiao Chai Hu Tang
Classic formula with Chai Hu as king herb at 24g — AMPK activation + hepatic glucose metabolism. For Shaoyang syndrome with metabolic dysfunction.
TCM Classification
Category: Harmonize Shaoyang / Soothe Liver Qi (和解少阳/疏肝)
Taste/Nature: Bitter, Pungent / Slightly Cold
Channels: Liver, Gallbladder, Pericardium, Triple Burner
Key Result: ~25-fold GLP-1 increase in NCI-H716 cells
TCM Standard
3–10
g/day decoction
3g raise Yang; 6–9g soothe Liver; 15–24g Xiao Chai Hu Tang.
Raise Yang Qi
3
g/day (low dose)
For raising clear Yang in mild fatigue/deficiency patterns.
Soothe Liver Qi
6–9
g/day
Primary therapeutic dose for Liver Qi stagnation.
Xiao Chai Hu Tang
15–24
g/day (king herb)
Classic Shaoyang formula dose. AMPK + hepatic metabolism.
Modern Extract
200–600
mg standardized extract
Standardized to saikosaponin content.
⚠ Duration Limit
Short Courses
Do NOT use long-term at high doses
Hepatotoxicity reports with chronic high-dose use.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
B. falcatum hexane fraction → GLP-1 ~25-fold
|
Preclinical | NCI-H716 / db/db mice | 100 mg/kg |
|
PMC3943199 |
|
SSc/SIRT6 hepatoprotection
|
Preclinical | MAFLD model | SSc |
|
2026 |
|
SSa insulin resistance — ERK/IκBα
|
Preclinical | IR model | SSa |
|
2024 |
Contraindications & Cautions
- Hepatotoxicity reports with long-term high-dose use (>6g/day raw)
- Avoid in Yin deficiency with rising fire
- Contraindicated in true Yin deficiency headache
- Strict dose limits — do NOT use in large doses long-term
Safety Profile
- Safe at standard 3–10 g/day in short courses
- Well-validated in Xiao Chai Hu Tang formula
- Strongest GLP-1 fold-change among all 13 herbs (~25×)
- Hepatotoxicity risk limits long-term use
GLP-1 Mechanisms (6 Identified)
1. Allantoin → Direct GLP-1 Secretion
Na 2015 (Nutrients): allantoin restored GLP-1 to ~85% of normal in STZ-diabetic rats, alongside ↑ insulin, ↓ HbA1c.
In Vivo
2. DYPS Polysaccharides → SCFA → GPR41/43 → GLP-1
DYPS prebiotic → Akkermansia/Faecalibacterium/Roseburia → acetate/propionate/butyrate → GPR41/GPR43 → GLP-1 exocytosis.
In Vivo
3. Dioscorin Hydrolysate → DPP-4 Inhibition
Peptic digestion of dioscorin generates DPP-4 inhibitory peptides → prolonged active GLP-1 half-life. In vivo: 50–80 mg/kg improved GTT.
In Vivo
In Vitro
4. Diosgenin → DPP-4 Inhibition + Insulin Secretion
Diosgenin DPP-4 IC50 = 12.75 ± 2.70 μM. Also stimulates insulin via PDE3B/AMPK/mTOR.
In Vitro
In Vivo
5. Dioscin → Bile Acid → TGR5 → GLP-1
Mao 2023: dioscin 80 mg/kg inhibits BSH bacteria → ↑ conjugated bile acids → TGR5 → GLP-1 mRNA↑. FMT-validated.
In Vivo
6. Low-GI Resistant Starch → Sustained L-Cell Stimulation
GI lower than brown rice; slow digestion delivers nutrients to L-cell-dense ileum/colon.
Clinical observation
Key Active Compounds
DYPS/CYP polysaccharides
Allantoin (GLP-1 + imidazoline)
Diosgenin (DPP-4 IC50 12.75 μM)
Dioscin (TGR5/GLP-1)
Dioscorin (DPP-4 peptides)
Resistant starch/glucomannan
One of the SAFEST Herbs
Food-grade herb (薯蓣, dietary yam). Virtually no toxicity at recommended doses. Classical usage up to 500g congee documented safely.
TCM Classification
Category: Tonify Spleen/Stomach, Lung, Kidney (健脾胃/肺/肾)
Taste/Nature: Sweet / Neutral
Channels: Spleen, Lung, Kidney
Key Formulas: Liu Wei Di Huang Wan, Yu Ye Tang, Shu Yu Wan
TCM Standard
9–30
g/day decoction
Standard tonifying dose.
Diabetes-Specific
50–250
g/day (large dose classical)
Used in Xiaoke (diabetes) classical formulas at high doses.
Liu Wei Di Huang Wan
RCT n=216
FBG 5.12 vs 6.35, HbA1c 6.58 vs 8.18%
vs insulin alone — significant improvement.
Meta-analysis
53 RCTs
n=4,905 (Zhang 2020)
HbA1c −0.84%, FBG −0.93 mmol/L, HOMA-IR −1.11.
Dioscin
80
mg/kg (TGR5/GLP-1 mechanism)
Mao 2023: bile acid → TGR5 → GLP-1 mRNA↑. FMT-validated.
Safety
One of the SAFEST
herbs in Chinese materia medica
Food-grade. Up to 500g congee safe in classical usage.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
Allantoin restores GLP-1 in STZ-diabetic rats
|
Preclinical | STZ-diabetic rats | Allantoin |
|
Nutrients 2015 |
|
Dioscin → TGR5/bile acid/GLP-1 — FMT-validated
|
Preclinical | Mouse model | 80 mg/kg dioscin |
|
PMC10657977 |
|
Shan Yao formulas meta-analysis
|
53 RCTs, n=4,905 | Various formulas |
|
PMC7685178 | |
|
DOTPs gut microbiota modulation
|
Preclinical | HFD mice | DOTPs |
|
PMC10563686 |
Contraindications & Cautions
- Avoid in excess dampness/stagnation patterns
- Very large doses theoretical only — monitor in modern clinical use
Safety Profile
- One of the SAFEST herbs in Chinese materia medica
- Food-grade herb (dietary yam)
- Virtually no toxicity at recommended doses
- Large meta-analysis (53 RCTs, n=4,905) supports safety
- No significant adverse events in clinical literature
GLP-1 Mechanisms (5 Identified)
1. Bitter Receptor TAS2R → L-Cell GLP-1 (Primary)
Iridoid glycosides (loganic acid) activate intestinal TAS2R → Gβγ/PLC-η/IP3/Ca²⁺ → GLP-1 secretion. Uses PLC-η (distinct from PLC-β) — mechanistically unique. Suh 2015: 100 mg/kg raised GLP-1 and insulin in db/db mice.
In Vivo
2. Gentiopicroside → FGF21/AMPK → Hepatic Glucose Control
GPS activates FGF21 → FGFR1 → PI3K/AKT/AMPK; inhibits hepatic gluconeogenesis (PEPCK↓, G6Pase↓ via FOXO1).
In Vivo
3. Amarogentin → Potent AMPK Activation
Amarogentin directly binds AMPK α2 subunit, EC50 = 277 pM (picomolar — among most potent natural AMPK activators known).
In Vitro
In Vivo
4. Swertiamarin → PPAR-γ Agonism → Insulin Sensitization
Swertiamarin activates PPAR-γ (via metabolite gentianine) → GLUT4↑, adiponectin↑; hepatic PEPCK↓/GK↑/GLUT2↑.
In Vivo
5. Long Dan Xie Gan Tang Formula → Hepatic IR
10-herb formula: ACE2/Ang(1-7)/Mas → AMPKα → SREBP-1c suppression + PPARα → fatty liver attenuation.
In Vivo
Key Active Compounds
Gentiopicroside/GPS (FGF21/AMPK)
Amarogentin (AMPK EC50 = 277 pM)
Swertiamarin → Gentianine (PPAR-γ)
Loganic acid (GLP-1 secretagogue)
Gentianine alkaloid
Amarogentin: Most Potent Natural AMPK Activator
Amarogentin EC50 = 277 picomolar — among the most potent natural AMPK activators known. Uses unique PLC-η signaling variant distinct from other herbs.
TCM Classification
Category: Clear Heat/Dry Damp (清热燥湿)
Taste/Nature: Bitter / Cold
Channels: Liver, Gallbladder
Key Formula: Long Dan Xie Gan Tang
IMPORTANT: Lower dose than most herbs — 2–6 g/day maximum
TCM Standard
2–6
g/day (LOWER than most herbs)
Potent and cold. Classical texts: 2–3 g for routine use.
Routine Use
2–3
g/day
Extended use or large doses damage Spleen Qi and injure Yin.
Formula Context
Long Dan Xie Gan Tang
king herb in Liver-Gallbladder formula
Hepatic insulin resistance evidence (Wang 2021, Ren 2019).
Amarogentin
EC50 = 277 pM
most potent natural AMPK activator
Picomolar potency — extremely small amounts active.
Gentiopicroside
FGF21/AMPK
hepatic glucose control
Inhibits PEPCK, G6Pase via FOXO1.
⚠ CAUTION
Short Courses ONLY
do NOT exceed 6g/day
Damages Spleen/Stomach at high doses. Not for long-term use.
| Study / Authors | Type | Model / n | Dose | Key Findings | Link |
|---|---|---|---|---|---|
|
G. scabra extract → GLP-1/insulin in db/db mice
|
Preclinical | db/db mice | 100 mg/kg |
|
PubMed ↗ |
|
Amarogentin AMPK EC50 = 277 pM
|
In Vitro | AMPK assay | Amarogentin |
|
In Vitro |
|
Gentiopicroside FGF21/AMPK axis
|
Preclinical | Hepatic model | GPS |
|
Preclinical |
|
Long Dan Xie Gan Tang — hepatic IR
|
Preclinical | Formula study | Formula |
|
Preclinical |
Contraindications & Cautions
- CAUTION — potent cold bitter herb
- Not for long-term use
- Damages Spleen/Stomach at high doses
- Contraindicated in Spleen deficiency diarrhea
- Do not use >6g/day
- Cases of digestive impairment with chronic use
Safety Profile
- Safe at 2–3 g in short courses
- Well-validated in Long Dan Xie Gan Tang formula
- Most potent natural AMPK activator (amarogentin)
- Strict dose and duration limits required
- Not suitable for long-term monotherapy
